22.5% - Search News

CNBC on MSN · 8h

Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

The Financial Times · 3h

Novo Nordisk shares fall on latest trial results for new obesity drug

Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy. The trial of CagriSema in patients who were obese or overweight and with type 2 diabetes failed to show a clear superiority to a drug from rival Eli Lilly,

Business Insider · 7h

Novo Nordisk down 6% after results for trial of weight-loss drug CagriSema

Shares of Novo Nordisk (NVO) trading in New York are down $5.22, or 6%, to $81.95 in the pre-market session.Discover the Best Stocks and

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

PI Price Down Whopping 22.5% in the Past 24 Hours – What Is Next?

Pi Network (PI) tumbles 22.5% in a day after Binance poll fuels speculation. Will PI recover, or is the downtrend set to ...

4don MSN

NC House GOP bill would raise teacher pay 22%. Does it have a chance of passing?

The legislation would provide teachers with raises ranging from $9,000 to $12.280 a year. Here’s how much it would cost.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results